Q32 Bio Inc. financial data

Symbol
QTTB on Nasdaq
Industry
Pharmaceutical Preparations
Location
830 Winter Street, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Homology Medicines, Inc. (to 3/22/2024)
Latest financial report
10-K - Q4 2024 - Mar 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 525 % +1.05%
Debt-to-equity 346 %
Return On Equity -180 % -618%
Return On Assets -40.3 % -4%
Operating Margin 528 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.2M shares +2.25%
Common Stock, Shares, Outstanding 12.2M shares +3292%
Entity Public Float 136M USD +198%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 9.32M shares +2570%
Weighted Average Number of Shares Outstanding, Diluted 9.66M shares +2667%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Revenue from Contract with Customer, Excluding Assessed Tax 1.16M USD -64%
Research and Development Expense 48.1M USD +51.7%
General and Administrative Expense 18M USD +81.9%
Operating Income (Loss) -66.1M USD -37%
Nonoperating Income (Expense) 20M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -87.1M USD -7369%
Income Tax Expense (Benefit) 21K USD -93.4%
Net Income (Loss) Attributable to Parent -47.7M USD +11.2%
Earnings Per Share, Basic -5.12 USD/shares +96.7%
Earnings Per Share, Diluted -6.58 USD/shares +95.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 78M USD +204%
Other Assets, Current 396K USD +377%
Assets, Current 81.9M USD +185%
Property, Plant and Equipment, Net 1.37M USD -23.1%
Operating Lease, Right-of-Use Asset 5.72M USD -9.19%
Other Assets, Noncurrent 116K USD -97.5%
Assets 92.3M USD +96.2%
Accounts Payable, Current 2.99M USD -13.8%
Employee-related Liabilities, Current 2.78M USD -7.36%
Accrued Liabilities, Current 7.48M USD -23.4%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 16.5M USD +16.7%
Operating Lease, Liability, Noncurrent 5.64M USD -9.8%
Other Liabilities, Noncurrent 55M USD 0%
Liabilities 86.7M USD -26.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -235M USD -25.5%
Stockholders' Equity Attributable to Parent 5.68M USD
Liabilities and Equity 92.3M USD +96.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.6M USD -16.4%
Net Cash Provided by (Used in) Financing Activities 99.3M USD +662207%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 12.2M shares +3292%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.47M USD -96%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 78.6M USD +151%
Deferred Tax Assets, Valuation Allowance 107M USD +94%
Deferred Tax Assets, Gross 109M USD +90.2%
Operating Lease, Liability 6.25M USD -7.93%
Depreciation 495K USD -53.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -47.7M USD +11.2%
Lessee, Operating Lease, Liability, to be Paid 8.12M USD +488%
Property, Plant and Equipment, Gross 2.82M USD +2.73%
Operating Lease, Liability, Current 612K USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.09M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.06M USD -23.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.87M USD +2921%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.12M USD
Deferred Tax Assets, Operating Loss Carryforwards 88.6M USD +15.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.16M USD
Additional Paid in Capital 240M USD +5682%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 4.39M USD +207%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%